Page 1 | Search Results | Blood Advances | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm

Alex Bataller, Georgina Gener-Ricos, Emmanuel Almanza-Huante, Kelly S. Chien, Samuel Urrutia, Alexandre Bazinet, Juan Jose Rodriguez-Sevilla, Danielle Hammond, Koji Sasaki, Koichi Takahashi, Courtney D. DiNardo, Farhad Ravandi, Gautam Borthakur, Tapan M. Kadia, Rashmi Kanagal-Shamanna, Hagop M. Kantarjian, Guillermo Garcia-Manero, Guillermo Montalban-Bravo

Blood Adv (2024) 8 (11): 2695–2706.

https://doi.org/10.1182/bloodadvances.2024012565

Published: 2024

Includes: Supplemental data

Journal Articles

Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax

Alex Bataller, Alexandre Bazinet, Courtney D. DiNardo, Abhishek Maiti, Gautam Borthakur, Naval G. Daver, Nicholas J. Short, Elias J. Jabbour, Ghayas C. Issa, Naveen Pemmaraju, Musa Yilmaz, Guillermo Montalban-Bravo, Koichi Takahashi, Sanam Loghavi, Guillermo Garcia-Manero, Farhad Ravandi, Hagop M. Kantarjian, Tapan M. Kadia

Blood Adv (2024) 8 (4): 927–935.

https://doi.org/10.1182/bloodadvances.2023011757

Published: 2024

Includes: Supplemental data

Journal Articles

Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2 -mutant myelodysplastic syndrome

Blood Adv (2023) 7 (11): 2378–2387.

https://doi.org/10.1182/bloodadvances.2022008378

Published: 2023

Includes: Supplemental data

Journal Articles

Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML

Blood Adv (2023) 7 (6): 933–942.

https://doi.org/10.1182/bloodadvances.2022008316

Published: 2023

Includes: Supplemental data

Journal Articles

High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse

Blood Adv (2022) 6 (13): 4006–4014.

https://doi.org/10.1182/bloodadvances.2022007378

Published: 2022

Includes: Supplemental data

Journal Articles

Outcomes of acute lymphoblastic leukemia with KMT2A ( MLL ) rearrangement: the MD Anderson experience

Guillaume Richard-Carpentier, Hagop M. Kantarjian, Guilin Tang, C. Cameron Yin, Joseph D. Khoury, Ghayas C. Issa, Fadi Haddad, Nitin Jain, Farhad Ravandi, Nicholas J. Short, Courtney D. DiNardo, Koichi Takahashi, Marina Y. Konopleva, Naval G. Daver, Tapan Kadia, Guillermo Garcia-Manero, Rebecca Garris, Susan O’Brien, Elias Jabbour

Blood Adv (2021) 5 (23): 5415–5419.

https://doi.org/10.1182/bloodadvances.2021004580

Published: 2021

Journal Articles

Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax

Blood Adv (2021) 5 (8): 2173–2183.

https://doi.org/10.1182/bloodadvances.2020004173

Published: 2021

Includes: Supplemental data

Journal Articles

Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia

Blood Adv (2021) 5 (7): 1876–1883.

https://doi.org/10.1182/bloodadvances.2020003717

Published: 2021

Includes: Supplemental data

Journal Articles

Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia

Nicholas J. Short, Guillermo Montalban-Bravo, Hyunsoo Hwang, Jing Ning, Miguel J. Franquiz, Rashmi Kanagal-Shamanna, Keyur P. Patel, Courtney D. DiNardo, Farhad Ravandi, Guillermo Garcia-Manero, Koichi Takahashi, Marina Konopleva, Naval Daver, Ghayas C. Issa, Michael Andreeff, Hagop Kantarjian, Tapan M. Kadia

Blood Adv (2020) 4 (22): 5681–5689.

https://doi.org/10.1182/bloodadvances.2020003120

Published: 2020

Includes: Supplemental data

Journal Articles

Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia

Blood Adv (2020) 4 (8): 1670–1677.

https://doi.org/10.1182/bloodadvances.2019001156

Published: 2020

Includes: Supplemental data

Journal Articles

Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens

Blood Adv (2020) 4 (7): 1311–1320.

https://doi.org/10.1182/bloodadvances.2019001267

Published: 2020

Includes: Supplemental data

Journal Articles

Genomic context and TP53 allele frequency define clinical outcomes in TP53 -mutated myelodysplastic syndromes

Blood Adv (2020) 4 (3): 482–495.

https://doi.org/10.1182/bloodadvances.2019001101

Published: 2020

Includes: Supplemental data

Journal Articles

Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL

Paolo Strati, Koichi Takahashi, Christine B. Peterson, Michael J. Keating, Philip A. Thompson, Naval G. Daver, Nitin Jain, Jan A. Burger, Zeev Estrov, Susan M. O'Brien, Hagop M. Kantarjian, William G. Wierda, P. Andrew Futreal, Alessandra Ferrajoli

Blood Adv (2019) 3 (9): 1533–1539.

https://doi.org/10.1182/bloodadvances.2019031336

Published: 2019

Journal Articles

NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy

Blood Adv (2019) 3 (6): 922–933.

https://doi.org/10.1182/bloodadvances.2018026989

Published: 2019

Includes: Supplemental data

Journal Articles

Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study

Guillermo Garcia-Manero, Yasmin Abaza, Koichi Takahashi, Bruno C. Medeiros, Martha Arellano, Samer K. Khaled, Mrinal Patnaik, Olatoyosi Odenike, Hamid Sayar, Mohan Tummala, Prapti Patel, Lori Maness-Harris, Robert Stuart, Elie Traer, Kasra Karamlou, Abdulraheem Yacoub, Richard Ghalie, Ruben Giorgino, Ehab Atallah

Blood Adv (2019) 3 (4): 508–518.

https://doi.org/10.1182/bloodadvances.2018027409

Published: 2019

Includes: Supplemental data

Journal Articles

Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis

Prajwal Boddu, Hagop M. Kantarjian, Guillermo Garcia-Manero, Farhad Ravandi, Srdan Verstovsek, Elias Jabbour, Gautam Borthakur, Marina Konopleva, Kapil N. Bhalla, Naval Daver, Courtney D. DiNardo, Christopher B. Benton, Koichi Takahashi, Zeev Estrov, Sherry R. Pierce, Michael Andreeff, Jorge E. Cortes, Tapan M. Kadia

Blood Adv (2017) 1 (17): 1312–1323.

https://doi.org/10.1182/bloodadvances.2017008227

Published: 2017

Includes: Supplemental data

Journal Articles

Copy number alterations detected as clonal hematopoiesis of indeterminate potential

Koichi Takahashi, Feng Wang, Hagop Kantarjian, Xingzhi Song, Keyur Patel, Sattva Neelapu, Curtis Gumbs, Latasha Little, Samantha Tippen, Rebecca Thornton, Courtney D. DiNardo, Farhad Ravandi, Carlos Bueso-Ramos, Jianhua Zhang, Xifeng Wu, Guillermo Garcia-Manero, P. Andrew Futreal

Blood Adv (2017) 1 (15): 1031–1036.

https://doi.org/10.1182/bloodadvances.2017007922

Published: 2017

Includes: Supplemental data

NARROW

Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm

Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax

Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2 -mutant myelodysplastic syndrome

Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML

High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse

Outcomes of acute lymphoblastic leukemia with KMT2A ( MLL ) rearrangement: the MD Anderson experience

Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax

Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia

Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia

Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia

Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens

Genomic context and TP53 allele frequency define clinical outcomes in TP53 -mutated myelodysplastic syndromes

Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL

NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy

Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study

Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis

Copy number alterations detected as clonal hematopoiesis of indeterminate potential

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only